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Case presentations
A 52-year-old woman with a history of alcohol abuse (more than 6
beers daily for years) was admitted to the hospital because of acute
precordial pleuritic pain that had begun abruptly 12 hours earlier. Three
weeks prior to admission she sought medical attention, for the first time
in 20 years, because of upper abdominal pain. An evaluation revealed
gastritis; she was also found to have hypertension, diabetes mellitus,
and chronic obstructive pulmonary disease. She discontinued ingesting
alcohol and began receiving treatment wth cimetidine (300 mg 4 times
daily), theophylline (200 mg twice daily), and clonidine, 0.1 mg, plus
chlorthalidone, 15 mg, in a combination preparation. One week prior to
admission she developed increased fatigue and nausea, but she denied
vomiting or diarrhea.
Physical examination at the time of admission revealed a disheveled,
thin, white female in no acute distress. The blood pressure was 190/100
mm Hg with a pulsus paradoxus of 8mm Hg; the pulse was 86 beats/mm
and regular. The skin was dry, no peripheral edema was present, and
the jugular venous pressure was normal. Funduscopic examination
revealed grade-I hypertensive retinopathy. Breath sounds were dimin-
ished bilaterally and a few scattered expiratory wheezes were heard. A
two-component, scratchy pericardial friction rub was apparent at the
left lower sternal border; an S4 was also heard. Cardiac examination
was otherwise unremarkable. The liver, palpable 3 cm below the right
costal margin, was slightly tender.
A chest film on admission showed hyperinflated lungs without
infiltrates and a normal-sized heart. The electrocardiogram revealed
voltage changes consistent with left ventricular hypertrophy; frequent
Presentation of the Forum is made possible by grants from CIBA
Pharmaceutical Company, Geigy Pharmaceuticals, and Sandoz,
Incorporated.
© 1985 by the International Society of Nephrology
premature atrial and ventricular beats also were present. There was a 2
to 3 mm elevation of the ST segments in leads III and V2-V4; the QT
interval was prolonged. Admission laboratory data revealed: hemoglo-
bin, 14 g/dl; hematocrit, 44%; white blood cell count, 20,800/mm3;
BUN, 8 mg/dl; creatinine, 0.8 mg/dl; and glucose, 154 mg/dl. Serum
electrolytes were: sodium 116 mEq/liter; potassium, 2.3; chloride, less
than 80; and bicarbonate, 40 mEq/liter. Arterial blood gas values on
100% oxygen were pH, 7.51; PCO2, 41; and P02, 201 mm Hg. Serum
magnesium was 2.2 mg/dl; calcium, 8.8 mg/dl; and phosphorus, 4.6 mg/
dl. Serum theophylline level was in the nontoxic range. Serum osmolali-
ty was 242 mOsmlliter, and a spot urine contained sodium, less than 10
mEq/liter; chloride, less than 15 mEq/liter; and potassium, 21 mEq/liter.
The CPK levels remained normal and there was no MB band.
Two hours after admission the patient had a seizure and the EKG
monitor revealed ventricular tachycardia followed by fibrillation. Car-
dioversion was successful and the patient was treated with lidocaine.
She subsequently developed atrial fibrillation, which persisted despite
correction of the hyponatremia and hypokalemia with administration of
saline and potassium chloride.
Discussion
DR. RICHARD L. TANNEN (Director, Division of Nephrology,
and Professor of Internal Medicine, The University of Michigan
Medical Center, Ann Arbor, Michigan): This woman presented
with severe hypokalemia 3 weeks after the initiation of diuretic
therapy. In association with the profound hypokalemia, she
manifested ventricular ectopy, which culminated in an episode
of ventricular tachycardia and fibrillation. In the course of my
discussion, I will address the role played by diuretics in the
development of her hypokalemia, and I will also consider the
relationship between hypokalemia and the development of the
cardiac arrhythmias.
Although it is widely recognized that diuretic therapy com-
monly results in hypokalemia, considerable controversy exists
regarding the clinical importance and appropriate management
of this complication [1—81. In this Forum I will (1) review the
pathophysiology of diuretic-induced hypokalemia; (2) summa-
rize the clinical characteristics of this condition; and (3) consid-
er when potassium maintenance therapy might be indicated in
patients receiving diuretic drugs. I will use the term "potassium
maintenance therapy" to refer to the use of either potassium-
chloride supplements or potassium-sparing drugs to maintain
normal potassium levels during diuretic therapy.
Pathophysiology of diuretic-induced hypokalemia
Diuretics that either inhibit reabsorption in the thick ascend-
ing limb of Henle (drugs such as furosemide, ethacrynic acid,
bumetanide) or in the early distal tubule (such as thiazides,
chlorthalidone) are kaliuretic and induce hypokalemia when
ingested on a chronic basis (Table 1) [1]. The kaliuresis pro-
duced by these agents results from increased delivery of tubular
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fluid to the distal convoluted tubule and also possibly from
increased sodium delivery to the distal nephron, especially the
cortical collecting duct [9—12]. The effect of increased distal
sodium delivery on potassium excretion may be enhanced by
the high aldosterone levels that are frequently present under
conditions of diuretic use.
In addition to the kaliuresis that results directly from the
diuretic properties of these drugs, at least one other pathophysi-
ologic process plays a critical role in the development and
maintenance of hypokalemia. Hypokalemia is sustained in
these patients in part as a result of the accompanying chloride
depletion. The role of chloride depletion was elucidated ele-
gantly by Schwartz and colleagues [13]. The major clinical
causes of primary chloride depletion are diuretic therapy and
the loss of gastric secretions from either vomiting or nasogastric
drainage. Because a low-sodium diet is also a low-chloride diet,
chloride depletion results from diuretic use because these
agents are chioruretic as well as natriuretic. As clearly demon-
strated in a sequence of studies by Schwartz and coworkers, a
primary deficit of chloride results in potassium depletion with
hypokalemia, metabolic alkalosis, and mild volume contraction
[13]. The volume contraction, which persists despite the provi-
sion of adequate dietary sodium, is not necessarily clinically
apparent. Similarly, so long as correction of the chloride deficit
is prevented—that is, by ingestion of a low-chloride diet—the
alkalosis is sustained because the daily production of endoge-
nous acid, otherwise more than sufficient in quantity to accom-
plish correction, is balanced by renal acid excretion. More
relevant to the present discussion is that the hypokalemia and
potassium deficiency persist despite the provision of adequate
potassium in the diet. All of the electrolyte abnormalities can be
corrected upon provision of adequate chloride to restore the
underlying deficit. These experimental observations provide
the cornerstone for the clinical principle that diuretic-induced
hypokalemia can only be managed successfully with the chlo-
ride salt of potassium, KCI. Other potassium salts such as those
of citrate, gluconate, and phosphate are ineffective in correcting
diuretic-induced hypokalemia secondary to chloride depletion.
It should be appreciated that this dependency on the chloride
salt of potassium applies only to potassium replacement therapy
and would not necessarily be the case if potassium-sparing
agents were used, because such agents interfere directly with
the renal tubule's capacity to secrete potassium.
The tubular mechanisms accounting for how chloride deple-
tion induces renal potassium losses are still unresolved. It has
been suggested that increased aldosterone secretion secondary
to volume depletion may account for the kaliuresis [14]. Al-
though elevated aldosterone levels may foster more intense
kaliuresis under conditions of diuretic use, it appears that
chloride depletion can result in potassium depletion even in the
absence of increased aldosterone levels [15—17]. An elevated
pH per se can increase renal potassium secretion and could play
a role in the potassium loss, but the magnitude of this effect is
unclear [18, 191. Finally, recent evidence suggests that the
concentration of chloride in distal tubule fluid can directly
influence potassium secretion. Although the precise mechanism
has not been elucidated, hypochioremia stimulates net potassi-
um secretion [20].
Thus it is clear that diuretics with sites of action at either the
ascending limb or the early distal tubule can produce kaliuresis
Table 1. Pathophysiology of diuretic-induced hypokalemia
I. Increased delivery of fluid to distal convoluted tubule
2. Increased delivery of sodium to distal nephron (? collecting duct)
3. Chloride depletion
a. Low C1 concentration in distal tubular fluid
b. Alkalosis
c. Increased aldosterone
4. Direct diuretic-induced stimulation of K secretion (?)
and potassium depletion by at least two mechanisms. Recent
experiments in our laboratory have raised the possibility that
diuretics, especially furosemide, might stimulate potassium
secretion in yet another way, namely by a direct tubular effect
[19]. These experiments, which utilized isolated perfused kid-
neys from potassium-depleted rats, indicated that furosemide
can induce a kaliuresis of a magnitude that cannot be accounted
for entirely by an increase in either urine flow rate or sodium
excretion. Furthermore, studies with amiloride indicated that
this direct effect of furosemide on potassium excretion resulted
from an increase in potassium secretion rather than from a
decrease in potassium reabsorption. Whether hydrochiorothia-
zide can also stimulate potassium secretion directly was not
definitively resolved by these experiments but, if hydrochloro-
thiazide has this property, its effect is much less prominent than
is that of furosemide. What, if any, role a direct effect of
diuretics on potassium secretion might play in vivo has not been
examined.
Clinical characteristics of diuretic-induced hypokalemia
The clinical characteristics of the abnormality in potassium
metabolism accompanying chronic diuretic use have been de-
fined carefully in the past decade [1, 2] and are summarized in
Table 2. We now know that the fall in serum potassium
concentration occurs rapidly and reaches a plateau within about
one week after diuretic therapy is initiated [21, 22]. As we will
consider shortly, the degree of hypokalemia with standard
doses of diuretics (hydrochlorothiazide, 50—100 mg/day or
equivalent doses of other thiazide diuretics; chlorthalidone, 50—
100 mg/day; furosemide, 40—80 mg/day) is modest [22—44]. Less
than 7% of patients taking thiazides and less than 1% of patients
taking furosemide exhibit a decrease in serum potassium below
3.0 mEq/liter [1, 211. For this reason, it is appropriate to
consider the possibility of other causes for hypokalemia in
patients whose serum potassium falls to less than 3.0 mEq/liter
during diuretic therapy. The patient today, whose serum potas-
sium was 2.3 mEq/liter on admission, is a case in point. In most
instances primary aldosteronism is high on the list of diagnostic
possibilities when hypertensive patients manifest this degree of
hypokalemia in response to treatment with diuretics. This
patient's hyponatremia and low urinary concentration of sodi-
um (less than 10 mEq/liter) and chloride (less than 15 mEq/liter)
at the time of presentation, and her ability to maintain normal
potassium levels later in the hospital course, made this an
unlikely possibility. Despite her denial, the impressive metabol-
ic alkalosis (serum HC03 of 40 mEqlliter) along with the low
urinary chloride concentration strongly suggest the possibility
of vomiting. Alternatively, her intake of diuretic could have
markedly exceeded the recommended dose. It is difficult to
distinguish between these latter two possibilities after the fact,
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Table 2. Clinical characteristics of diuretic-induced hypokalemia
1. Plasma K stabilizes in one week
2. 1%—7% of patients exhibit decreased plasma K to less than 3.0
mEq/liter
3. Degree of hypokalemia related to Na intake
a. Very low or high Na accentuates hypokalemia
b. Modest Na restriction (100 mEq/day) minimizes the degree of
hypokalemia
4. Females are more susceptible to hypokalemia than are males
5. Whites are more susceptible to hypokalemia than are blacks
6. No clear difference in the degree of hypokalemia exists whether
treatment is for hypertension or for CHF
since they both result in chloride depletion and therefore in a
similar clinical picture.
Several other clinical features of chronic diuretic use are
worth mentioning. Women seem to be more prone to hypokale-
mia than men seem to be [45], and some data suggest that
whites are more susceptible than are blacks [44]. The degree of
hypokalemia is minimized by moderate sodium restriction
(—60—110 mEqiday). Both severe sodium restriction (<20 mEq/
day) and a more liberal sodium intake (200 mEq/day) appear
to accentuate the magnitude of diuretic-induced hypokalemia
[23, 24]. Finally, although one might surmise that patients
treated with diuretics for congestive heart failure would be
more prone to severe hypokalemia than would those treated for
uncomplicated hypertension, this expectation is not supported
by the available data [8, 21, 46].
The magnitude of the fall in serum potassium and in the
degree of potassium depletion induced by chronic diuretic
therapy has been reviewed by several authors; the data summa-
rized in Table 3 were obtained in patients treated with standard
doses of diuretics and without potassium maintenance therapy
[1, 21]. The average decrement in plasma potassium with
thiazides is 0.6 mEq/liter; this decrement appears to be signifi-
cantly greater than the average decline of 0.3 mEq/liter with
furosemide therapy [21]. With chiorthalidone the decline in
plasma potassium is equivalent to that with thiazides [21].
Considerable variability has been found in the degree of
actual total body potassium depletion measured either with
total body counter or with exchangeable potassium techniques.
The data available prior to 1977 were carefully assessed by
Kassirer and Harrington, and the reports that have appeared
since that time are consistent with their earlier analysis [1, 22—
43]. As Table 3 shows, estimated deficits have ranged from as
low as 0 to as high as 400 mEq (0% to 10% body potassium
deficit) with all three classes of diuretics. Several studies have
failed to detect a significant decrease in total body potassium
and some investigators have concluded from these findings that
diuretic-induced hypokalemia occurs independently of a de-
crease in intracellular potassium stores. An analysis of multiple
studies, however, yields the mean values presented in Table 3.
This analysis suggests that the average deficit is approximately
200 mEq, equivalent to a 5% decline in total body potassium
stores. Given the limited sensitivity of the methods available, it
is not surprising that estimated deficits ranging from 0% to 10%
would be reported in the presence of a real deficit of this
magnitude. Indeed, the recent analysis by Sterns et al of pure
potassium depletion in humans described a strong correlation
(r = 0.9) between the magnitude of the potassium deficit and the
Table 3. Altered potassium balance in hypertensive patients treated
with diuretics
Plasma K
Mean
K Balance
Mean Rangec
(n)b mEq/liter ()b mEq mEq
Thiazides
Chlorthalidone
(50 mg/day)
Furosemide
(40—80 mg/day)
510
380
181
—0.58
—0.67
—0.30
230
82
46
—163
—274
—186
0—405
106—707
2—338
Adapted from Ref. 21.
b Number of patients.
Refers to the mean deficit recorded in each study.
d 50—100 mg/day of hydrochiorothiazide or equivalent dose of another
thiazide.
decrease in plasma potassium, with a decrease in plasma
potassium of 0.3 mEq/liter being associated on average with a
deficit of 100 mEq [47]. In line with this analysis, a decline of
0.3 mEq/liter would be expected with a deficit of 100 mEq and a
decline of 0.6 mEq with a deficit of 200 mEq; these values agree
reasonably well with the mean decrements measured with
thiazides and furosemide. Direct measurements of muscle po-
tassium concentrations also are consistent with this conclusion
[1, 41—43].
Hence, it seems reasonable to conclude that diuretic-induced
hypokalemia is associated with a decline in total body potassi-
um stores, but that the total potassium deficit is quite modest.
As with other potassium depletion states, the percent fall in
plasma potassium of 15% (that is, 0.6/4.0 mEq/liter) is greater
than the percent fall in intracellular potassium of 5%; thus, the
ratio of extracellular to intracellular potassium (Ke/Ki) is re-
duced. Furthermore, in view of the ability of the myocardium to
protect its cellular potassium content more effectively than
other muscle tissue can, alterations in the potassium gradient
may be even more pronounced in cardiac tissue [48, 49].
Indication for potassium maintenance therapy
Whether potassium maintenance therapy should be employed
to correct mild diuretic-induced potassium deficiency obviously
depends on the risks of mild potassium depletion as contrasted
with the risks and costs of possible therapeutic interventions.
First, I would like to consider the risks of potassium depletion
in this setting.
Risks of diuretic-induced hypokalemia and potassium deple-
tion. Mild degrees of experimentally induced potassium deple-
tion (that is, 200—300 mEq) modify renal ammonia production
and urinary acidification and also perturb the renal concentrat-
ing mechanism [50, 51]. The former effect may be a physiologic
adaptation [50], but the concentrating defect is a pathophysio-
logic byproduct of potassium deficiency. Although impaired
urine concentration is not of particular clinical importance, its
occurrence does emphasize that even mild potassium depletion
can induce organ dysfunction.
The potentially important clinical consequences of diuretic-
induced hypokalemia are listed in Table 4. Recent interest has
focused especially on the issue of hypokalemia-induced ventric-
ular arrhythmias. To properly address this question, I will
divide the issue into two subsets: (1) an increase in serious
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Table 4. Adverse consequences of diuretic-induced hypokalemia
1. Ventricular arrhythmias
a. Increased ventricular premature beats
b. Increased risk of ventricular tachycardia and ventricular
fibrillation with acute MI
2. Impaired hypertensive control
3. Glucose intolerance
4. Lipid abnormalities (?)
ventricular arrhythmias in stable patients with or without
underlying cardiac disease, and (2) an increased risk of ventric-
ular tachycardia or fibrillation in the setting of acute myocardial
infarction.
It is widely appreciated that hypokalemia can provoke ar-
rhythmias in patients treated with digitalis. Several recent
publications have suggested that hypokalemia per se increases
the risk for development of ventricular arrhythmias [33, 52—771.
The ventricular ectopy varies from an increase in the frequency
of unifocal ventricular premature beats to the development of
complex ventricular arrhythmias, including multifocal ventricu-
lar premature beats, ventricular couplets, and/or ventricular
tachycardia. In a recent critical review of this topic, Harring-
ton, Isner, and Kassirer pointed out that a clear association
between hypokalemia and ventricular arrhythmias could be
established only if: (1) other causes of ventricular ectopic
activity were rigorously excluded; (2) a firm temporal relation-
ship between the development of hypokalemia and ventricular
ectopy were demonstrated; and (3) correction of the underlying
potassium deficit was associated with alteration of the ventricu-
lar ectopy [5]. Indeed, of the 17 reports they analyzed, only one
fulfilled these three criteria [5, 52—67], and all but one were case
reports or retrospective analyses of data.
Today's patient illustrates the difficulty in delineating a clear
association between hypokalemia and arrhythmias. Hypokale-
mia certainly could have been a significant factor in either
directly producing or substantially increasing the susceptibility
for the development of ventricular ectopy. However, in view of
the underlying pericarditis and the severe hypoosmolality com-
plicated by a seizure, it is impossible to delineate the precise
role, if any, hypokalemia played in the abnormal rhythm.
Since publication of the review by Harrington et al, several
prospective studies have appeared that specifically address this
question in patients with diuretic-induced hypokalemia [33, 55,
68—77]. Table 5 summarizes these prospective studies. In three
of them, in which a total of 50 patients were examined, and also
in the chronic phase (3 to 50 month treatment) of the large
Medical Research Council (MRC) study, in which an additional
74 patients were examined, an increase in the frequency of
ventricular premature beats was noted to occur with the devel-
opment of diuretic-induced hypokalemia [33, 55, 70—74, 77].
Approximatey 25% to 50% of patients exhibited a susceptibility
to more frequent ventricular premature beats and, furthermore,
the development of complex ventricular ectopy was also noted
in 15% to 30% of patients in these four positive studies. In
contrast to these findings is the absence of a significant change
in ventricular ectopy in the short-term (9 to 10 week) MRC
study of 16 patients as well as in three other studies encompass-
ing 48 patients [68, 69, 71—73, 75, 76].
A similar lack of uniformity is apparent in the data collected
during normalization of plasma potassium concentration. Three
studies encompassing 35 patients reported an improvement in
ventricular premature beats [55, 71—74]; one study reported
improvement only with simultaneous potassium and magne-
sium therapy [70]; and one study of 16 patients found no
improvement with an increase in plasma potassium concentra-
tion to 3.7 mEq/liter [68].
It is of note that Caralis and coworkers found evidence of
hypokalemia-induced arrhythmias only in a subset of patients
who had preexisting, significant cardiac disease as documented
by abnormal results on EKGs, chest films, and 24-hour Holter
monitor [74]. In all the other studies, criteria specifically
excluded patients with angina, previous myocardial infarctions,
abnormal exercise tests, or high-grade ventricular ectopy. Only
patients without any evidence of heart disease or with mild
cardiomegaly documented by a chest film, left ventricular
hypertrophy by voltage criteria, or nonspecific EKG changes
were included in these other studies. Thus, the possibility exists
that a specific subset of patients, perhaps those with underlying
cardiac disease, is at particular risk; but if so, we certainly lack
the capacity to identify them uniformly.
Nevertheless, when this recent group of prospective studies
is considered in conjunction with the other reports in the
literature, the evidence seems to indicate that diuretic-induced
hypokalemia can result in ventricular ectopy and that the type
of ectopy can fall into the complex category, which has
ominous implications. The data suggest that the risk of complex
ventricular ectopy may be higher when the serum potassium is
3.0 mEq/liter or less; however, it seems clear that this complica-
tion can also arise with milder degrees of hypokalemia.
Even given these conclusions, to truly assess adverse conse-
quences it is necessary that we know the actual risk of
morbidity and mortality associated with the development of
ventricular ectopy. One recent study that followed patients for
up to 10 years suggests that asymptomatic, healthy individuals
without underlying cardiac disease experience no increased risk
of death from frequent and complex ventricular ectopy that
occurs spontaneously [78]. Whether this prognosis would apply
to patients with hypokalemia-induced arrhythmias is unknown.
Furthermore it is widely accepted that ventricular ectopy
predisposes to sudden death in patients with underlying isch-
emic heart disease [78—80]. Because the patient population
receiving diuretics for hypertension is at increased risk for
ischemic heart disease, and those undergoing therapy for con-
gestive heart failure have established cardiac disease, one might
speculate that diuretic-induced ventricular ectopy is likely to be
more ominous than is spontaneously occurring ectopy in an
otherwise healthy individual.
Several recent publications have addressed the role of hypo-
kalemia in the occurrence of arrhythmias at the time of acute
myocardial infarction [56, 57, 64, 81—86, 87]; this topic was
reviewed recently by Solomon [81]. An analysis of the data
from six studies, including a total of 8327 patients, is provided
in Table 6 and reveals a number of salient and reasonably
consistent observations. First, and most important, the inci-
dence of serious ventricular arrhythmias (that is, ventricular
tachycardia and/or fibrillation) was increased significantly in
every study in the presence of hypokalemia (defined as a serum
potassium less than either 3.6 or 3.5 mEq/liter). In most studies,
the incidence of combined ventricular tachycardia and fibrilla-
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Table 5. Diuretic-induced ventricular arrhythmias in hypertensive patients
Induction of hypokalemia Correction of hypokalemia
Number of Mean serum K Complex Mean serum K
Reference patients mEq/liter VPBSb VPBs mEqiliter VPBs
Holland et al [55, 77] 21 3.0 1' b t 4.0 b
Hollifield & Slaton [33, 701 13 3.4 ¶ 4.2
Caralis et al [74] 16 3.5 ¶ 1 4.1
MRC [7 1—73]
Acute (9—10 weeks) 16 3.6 NCb NC
Chronic (3—50 months)
Papademetriou et al [68]
74
12
16
3.6
2.8
1 ¶
3.5
3.7 NC
Papademetriou et al [69] 15 3.0 NC NC
Madias et al [75] 20 3.0 NC NC
Leif et al [761 13 3.0 NC NC
a Numerals in brackets are reference numbers.
b Symbols: VPB, ventricular premature beat; ¶, increase; ., decrease; NC, no change.
tion during the first 1 or 2 days of hospitalization was reported
[56, 57, 83, 84]; however, in the two series with the lowest
incidence of arrhythmias, the data are provided in a different
fashion. Hulting only reported the incidence of ventricular
fibrillation during the first 12 hours of hospitalization [64], and
Johansson and Dziamski only provided data on the incidence of
malignant arrhythmias resulting in circulatory arrest [85]. Al-
though these specific events occurred less frequently than did
the combination of ventricular tachycardia and ventricular
fibrillation, in general the increased frequency in the hypokale-
mic group followed a similar pattern and was from two- to
fourfold greater.
Whereas the likelihood of malignant arrhythmias complicat-
ing an acute myocardial infarction appears to be higher in the
presence of hypokalemia, the data suggest that the frequency of
ventricular premature beats is not increased [56, 57, 81, 841.
Consistent with this view is one recent series (not included in
Table 6) that analyzed the incidence of all arrhythmias in 103
patients with an acute myocardial infarction and found no
significant difference between hypokalemic and normokalemic
patients, although the frequency of arrhythmias was 72% with
hypokalemia compared with 58% in its absence (86).
Several other important observations emerge from these
studies. Although patients taking digitalis were not specifically
excluded, the data in three studies were analyzed to address the
possible role of digitalis. The increased frequency of malignant
arrhythmias with hypokalemia appeared to be independent of
this agent [56, 57, 81, 84].
Evaluation of the role of diuretics suggests that they are a
potential significant risk factor because of their propensity to
cause hypokalemia. Indeed, in every study the incidence of
hypokalemia was approximately twofold greater or more in
patients treated with diuretic medication [56, 57, 64, 83—85].
Furthermore, normokalemic patients treated with diuretics
were not at increased risk for malignant arrhythmias in compar-
ison with those not receiving diuretics; this finding indicates
that it is the increased likelihood of hypokalemia rather than the
diuretics per se that results in an increased risk for this
complication [56, 57, 83, 85].
Approximately 10% of the patients who have not received
antecedent therapy with diuretics exhibit hypokalemia in asso-
ciation with an acute myocardial infarction [57, 83—85]. This
raises the possibility that hypokalemia might reflect a shift in
potassium into the intracellular compartment, which might be
the result of the increased sympathic adrenal activity that can
accompany an acute myocardial infarction [88]. Indeed, the
possibility arises that hypokalemia is a marker, rather than the
primary cause of the arrhythmogenic potential, both of which
result from an increase in cathecholamines. Nonetheless, the
degree of hypokalemia induced by epinephrine appears to be
more profound in the presence of preexisting diuretic-induced
potassium depletion; this additive effect on lowering serum
potassium could increase the likelihood that a serious arrhyth-
mia will develop [88]. Another criticism of a primary role for
potassium depletion in the induction of ventricular arrhythmias
is that in many studies the level of potassium used for analysis
was not necessarily recorded prior to the development of the
arrhythmia [57, 64, 85]. The pitfall of measurement after an
acute episode is emphasized by the observations by Thompson
and Cobb, who found that 49% of patients resuscitated out of
hospital for ventricular fibrillation were hypokalemic, as com-
pared with 19% of patients admitted to the hospital with an
acute myocardial infarction, and 9% of ambulatory patients
with coronary heart disease [53]. However, the percentage of
patients taking diuretics did not differ among these three groups
and, in the resuscitated group, the serum potassium after
resuscitation did not differ between those who had and those
who had not received antecedent diuretic therapy. The authors
concluded that the high incidence of hypokalemia in the resusci-
tated group resulted from the resuscitative effort itself, and they
cautioned against inferring from these data that hypokalemia
predisposes to ventricular fibrillation. Nevertheless, in defense
of the suggestion that preexisting potassium depletion might
predispose to arrhythmias, several of the reports in Table 6
contained data based solely on the serum potassium level at the
time of admission to the hospital [56, 83, 84].
In none of the studies cited in Table 6 was a significant
increase in malignant arrhythmias reported in the diuretic- as
compared with nondiuretic-treated patients. However there is
also no information provided regarding which diuretic-treated
patients received potassium maintenance therapy [56, 57, 64,
83—85]. Thus, although these observations raise significant
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Table 6. Relationship of serum potassium to ventricular tachycardia
(VT) and ventricular fibrillation (VF) in patients with acute
myocardial infarction
Number of
Incidence of VT/VF
Hypokalemiaa Normokalemia
Reference patients % %
Solomon & Cole [57] 151 48 21
Nordrehaug [56] 1035 29 17
Hulting [64]b 537 8 2
Dyckner et al [83] 676 50 37
Reuben [841 586 21 5
Johansson & Dziamski
[85]C 5342 16 7
a Serum potassium < 3.5 or 3.6 mM.
b VF in first 12 hours after admission.
Malignant arrhythmias producing circulatory arrest.
concern that antecedent diuretic-induced hypokalemia might be
a risk factor for sudden death in patients sustaining an acute
myocardial infarction, the data available do not definitively
resolve this issue.
Two further studies deserve mention, however, because they
do heighten the concern that diuretic therapy might predispose
toward sudden death. Ruberman and colleagues found a two-
fold increase in sudden coronary death in patients treated with
diuretics during the 5-year period following an acute myocardial
infarction [80]. Furthermore, in the Multiple Risk Factor Inter-
vention Study (MRFIT), the incidence of sudden death was
increased twofold in the hypertensive group with EKG abnor-
malities receiving special intervention as compared with those
receiving the usual care [89, 90]. Speculation has been raised
concerning a possible role for diuretic therapy, because diuret-
ics were the prescribed step-l antihypertensive drug in the
special intervention group. Thus, a substantial body of evidence
raises serious concerns about the possibility that diuretic-
induced hypokalemia might predispose toward sudden death,
especially in settings of underlying cardiac disease; but the
evidence is still not conclusive.
The most dramatic potential adverse effect of diuretic-in-
duced hypokalemia is ventricular arrhythmia and sudden death,
but there are other potential consequences of persistent, mild
hypokalemia. The relationship between potassium homeostasis
and blood pressure recently has been a subject of considerable
attention. The data indicate that both high and low potassium
levels can exert antihypertensive effects [91]. Indeed, potassi-
um interacts with so many blood pressure regulatory systems
that it is impossible to predict, a priori, how diuretic-induced
hypokalemia would alter blood pressure in patients undergoing
treatment for hypertension. This question was investigated
recently in a carefully controlled, double-blind, crossover ex-
amination of potassium supplementation in hypertensive pa-
tients treated with diuretics [92]. Correction of hypokalemia
resulted in a small but statistically significant decline in blood
pressure. It would be premature for us to extrapolate broadly
from this small study on a selected group of hypertensives to
the population at large, but these data do suggest that treatment
of hypokalemia might improve blood pressure control in at least
some hypertensive patients.
Glucose intolerance is an additional, well-defined complica-
tion of diuretic-induced hypokalemia [93, 941. Whereas some
data suggest that diuretics per se can interfere with glucose
metabolism [95], the bulk of evidence indicates that hypokale-
mia accounts for the development of glucose intolerance in
patients treated with diuretics [96—103]. Experimental potassi-
um depletion induces glucose intolerance, and insulin-clamp
studies indicate that the primary abnormality is a defect in
insulin release with no change in the insulin sensitivity of the
tissue [96, 97]. Hypokalemia also can impair the conversion of
proinsulin to insulin, but this abnormality has not been repro-
duced with experimental potassium deficiency [97, 104]. Diuret-
ic-associated glucose intolerance does not occur when potassi-
um depletion is prevented [98], correlates with the development
of hypokalemia [100, 103], and can be corrected by normaliza-
tion of the potassium deficit [99, 101, 1021.
The magnitude of potassium deficiency required for the
development of glucose intolerance is modest and consistent
with the degree of depletion that develops in many diuretic-
treated patients. Rowe observed glucose intolerance following
experimentally produced potassium deficits of 1,0% to 8.4%
that were documented by total body potassium counting [961.
Other authors using balance techniques have observed abnor-
malities in glucose metabolism with mild to moderate potassium
depletion (that is, deficits ranging from 200 to 569 mEq) [97,
105].
These observations support both the primacy and likelihood
of potassium depletion in the development of disordered glu-
cose homeostasis. It has been estimated that 30% of hyperten-
sive patients receiving thiazide diuretics exhibit abnormal glu-
cose tolerance, and population studies with adequate controls
clearly indicate that development of glucose intolerance is
causally related to diuretic therapy [100, 101, 103]. In most
instances, only mild glucose intolerance develops and does not
require hypoglycemic therapy; but rarely overt diabetes be-
comes manifest [4]. The potential risk, therefore, relates mainly
to whether the subtle abnormalities in glucose metabolism
predispose toward accelerated cardiovascular disease. This
issue is unresolved in the selected population of patients with
diuretic-induced glucose intolerance.
A potential relationship between diuretic use and lipid abnor-
malities is less clear than for glucose intolerance [93]. Most but
not all studies suggest that therapy with thiazide or chlorthali-
done results in an increase in cholesterol and triglyceride
concentrations and in the ratio of low- to high-density lipopro-
tein cholesterol [93, 101, 106—113]. Two large, well-controlled
investigations both uncovered a significant lipid alteration in
patients treated with diuretics [106, 107]. The mechanism
underlying the abnormality in lipid metabolism and its relation-
ship to hypokalemia are unknown [931. The latter issue requires
careful study, and the cardiovascular risk of the lipid abnormali-
ty also needs to be delineated.
Potassium maintenance therapy, A decision regarding the
appropriateness of potassium maintenance therapy must bal-
ance the adverse consequences of such a treatment program
against the litany of potential hypokalemia-induced side effects.
Potassium maintenance therapy can be accomplished success-
fully either with the use of potassium chloride supplements or
with the use of potassium-sparing diuretics (such as aldactone,
triamterene, or amiloride). Each of these approaches can cor-
rect diuretic-induced hypokalemia, but it should be recognized
that KC1 in doses of 40 to 60 mEq/day is needed for adequate
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therapy [1141. The data also suggest that potassium-sparing
agents may be somewhat more effective in normalizing potassi-
um than are potassium supplements [211.
Regardless of which approach to potassium maintenance
therapy is used, the most serious risk is the development of
hyperkalemia, a life-threatening complication. Whereas the risk
of this complication has not been well-defined for the non-
hospitalized patient, 3.9% of 1910 hospitalized patients who
received oral potassium chloride developed significant hyperka-
lemia (potassium greater than 5.5 mEq/liter) [1151. Of hospital-
ized patients treated with spironolactone without potassium
supplements, hyperkalemia occurred in 5.7% [116]. Compara-
bly large studies have not been reported with the potassium-
sparing drugs triamterene and amiloride, but the risks of
hyperkalemia with these drugs are well documented. Regard-
less of whether potassium supplements or potassium-sparing
diuretics were used, renal impairment was an important factor
predisposing to hyperkalemia. The elderly and patients who
received potassium in addition to potassium-sparing drugs are
also at increased risk for the development of hyperkalemia [6,
115, 1161. Although these data indicate that hyperkalemia is a
risk of potassium maintenance therapy, they do not establish
the incidence of clinically significant hyperkalemia in ambula-
tory patients with acceptable levels of renal function treated
selectively with either potassium supplements or potassium-
sparing agents.
In addition to hyperkalemia, other adverse consequences of
potassium maintenance therapy can occur that are drug-specif-
ic. All forms of KC1 (liquid, wax matrix, and polymer-coated
microencapsulated products) entail a risk of gastrointestinal
ulceration, although the incidence of clinically significant ulcer-
ation appears to be low. Spironolactone can cause estrogen-like
side effects, and triamterene can produce renal stones as well as
folate-deficiency anemia [117]. In addition, both these agents as
well as amiloride are associated with gastrointestinal side
effects, and there also exists the risk of drug-induced allergic
manifestations.
Finally, a substantial economic cost is associated with potas-
sium maintenance therapy, regardless of whether potassium
supplements or potassium-sparing diuretics are employed. Har-
rington and Kassirer estimated a few years ago that $250 million
per year is spent for potassium treatment in the U.S. [5].
Therapeutic recommendations
Given this body of information, the physician is confronted
with the need to make a decision regarding the use of potassium
maintenance therapy. All would welcome a well-designed trial
to assess the risk-benefit ratio of potassium maintenance treat-
ment in order to arrive at a therapeutic strategy, but it seems
unlikely that a study of appropriate scope and design will be
carried out in the near future. Hence, a treatment plan must be
formulated based on the incomplete data currently available.
My personal biases are listed in Table 7. There is general
agreement that potassium maintenance treatment is indicated in
patients receiving digitalis, in those predisposed to hepatic
coma, or in those in whom serum potassium falls to less than 3.0
mEq/liter [1,2,6]. In view of the well-defined risks of hypokale-
mia-induced arrhythmias in patients treated with digitalis, and
in view of the capacity for hypokalemia to induce hepatic
encephalopathy by stimulating renal ammonia production,
Table 7. Indications for potassium maintenance therapy
1. Digitalis therapy
2. Predisposition to hepatic coma
3. Serum potassium < 3.0 mEq/liter
4. Development of glucose intolerance
5. Underlying cardiac disease
6. Symptoms attributable to hypokalemia
there is a broad concensus that the risks of hypokalemia in
these settings outweigh those of therapy. Similarly, when serum
potassium falls below 3.0 mEq/liter, the likelihood of hypokale-
mia-induced cardiac, muscular, and gastrointestinal symptoms
are increased and, despite the absence of rigorous proof, there
appears to be no argument that the risk of therapy is justified
under this circumstance.
The last three indications listed in Table 7 are more contro-
versial. In my view, treatment is indicated in any patient who
develops overt glucose intolerance, because this disorder may
represent a pathologic sequela of hypokalemia. Whereas the
long-term risk of mild glucose intolerance is undefined, the risks
of potassium maintenance therapy are small and seem appropri-
ate to forestall the potential sequelae of accelerated cardiovas-
cular disease.
The fifth indication, that is, to treat any patient with underly-
ing cardiac disease, evokes the most heated debate. It is based
on a judgment regarding the potential risk for hypokalemia-
induced ventricular arrhythmias both under stable conditions
and in the setting of an acute myocardial infarction. My
rationale is as follows: Although some studies do not reveal an
increased risk of ventricular arrhythmias in patients with diuret-
ic-induced hypokalemia, several carefully performed evalua-
tions have uncovered a statistically significant alteration. Fur-
thermore, complex as well as unifocal ventricular arrhythmias
have been delineated. Because the failure to detect an effect
does not prove its absence, the disparate findings can be
interpreted as suggesting that the groups selected for study
differed, perhaps in ways we are not yet sophisticated enough to
identify. In this regard, the study by Caralis and colleagues
points strongly to the presence of underlying cardiac disease as
an important risk factor for hypokalemia-induced ventricular
arrhythmia [74]. In view of the documented increased risk of
sudden death in patients with ventricular arrhythmias superim-
posed on underlying cardiac disease, I believe that potassium
maintenance therapy, judiciously monitored, is a preferable
alternative to hypokalemia. My convictions are strengthened by
the data regarding the risk of hypokalemia in the setting of acute
myocardial infarction. Granted that each of these studies is
subject to criticism, the evidence as it currently exists suggests
that there is, rather than is not, a real risk of sudden death in
patients with preexisting potassium depletion.
These two lines of reasoning lead to my conclusion that
potassium maintenance therapy should be used if cardiac
disease is evident. The corollary is that I would not routinely
advise potassium maintenance therapy for patients receiving
diuretics who do not have evidence of underlying cardiac
disease. This subgroup would seem to be less prone to arrhyth-
mias, to be at less risk if arrhythmias develop, and is probably
at less risk for development of an acute myocardial infarction.
My final recommendation is to initiate a trial of potassium
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maintenance therapy in any patient with symptoms that can be
ascribed to hypokalemia. This includes a variety of vague
complaints including malaise, fatigue, muscular weakness, and
muscle cramps. Granted that all these symptoms are nonspecif-
ic, but they nevertheless can be manifestations of potassium
depletion. If therapy relieves the symptoms, the response could
be due either to specific correction or to a placebo effect. In
either case, long-term potassium maintenance treatment would
seem indicated, as the patient experiences a benefit and the
risks are minimal.
Questions and answers
DR. DAVID BUSHINSKY (Renal Section, Mitchell Hospital,
Chicago): Many authorities recommend that antihypertensive
therapy begin with the use of diuretic agents. In view of the
risks of hypokalemia, would you recommend the use of agents
other than diuretics as first-line therapy in the treatment of
hypertension?
DR. TANNEN: This issue is certainly pertinent in view of the
finding in the MRFIT study that the special intervention group
(which was treated with diuretics) had an increased incidence of
unexplained sudden death [89, 90], and the report by Ruberman
et al of a twofold increase in the rate of sudden death in patients
treated with diuretics following an acute myocardial infarction
[801. Neither of these studies definitively incriminates diuretics
as the culprit however. Furthermore, the long-term risks of the
other antihypertensive therapies are not well delineated. Di-
uretics are relatively safe and have few unpleasant side effects,
so I still recommend them as first-line antihypertensive drugs.
However, if the patient has underlying cardiac disease, I
concurrently recommend potassium maintenance.
DR. GARY TOBACK (Renal Section, Mitchell Hospital): What
drug do you use for the management of diuretic-induced
hypokalemia?
DR. TANNEN: I formerly favored potassium chloride supple-
mentation. However, you have to use enough KC1—40 to 60
mEq/day and in some instances more—to maintain normal
serum potassium levels, and recent data in the literature suggest
that potassium-sparing agents are more effective in sustaining
normal serum potassium levels than is potassium chloride. In
addition, both triamterene and amiloride are well tolerated by
most patients. My current bias leans towards amiloride, which I
think is a little bit more predictable and perhaps better tolerated
in terms of side effects. But that is a personal bias and I think
one can make arguments for using the other forms of potassium
maintenance therapy as well.
DR. TOBACK: I would like to hear your comments about the
relationship between hypokalemia and cardiac injury. It is not
talked about much anymore, but the older pathology literature
suggested that the ingestion of a potassium-deficient diet could
result in myocardial necrosis, which could become striking
when potassium deficiency was marked [118]. In addition to
death of myocardial cells, there appears to be a proliferation of
fibroblasts [118]. So if there is underlying heart disease, one
could argue that there might be cells suffering from borderline
ischemia and that hypokalemia might cause enough further
damage to make sublethally injured cells become necrotic. I
wonder if you would comment on that.
DR. TANNEN: In the 40-year-old literature that you are
quoting, Dr. Toback, the patients and the animal models
studied were severely potassium deficient, and the clinical
studies often had other complicating features [1171. Whether
milder degrees of potassium depletion can in some way sensi-
tize the cell to ischemic injury, for example, has not been
addressed to my knowledge, but I think it is a reasonable issue
to consider. Furthermore, potassium has direct effects on the
vasculature: a high potassium concentration is vasodilatory and
a low potassium concentration is vasoconstrictive. The Sodi-
Pallares solution, which contains potassium, insulin, and glu-
cose, might confer benefit by delivering more potassium to
ischemic sites and thus produce vasodilation and improved
perfusion of ischemic areas. I am unaware, however, of any
convincing studies utilizing this approach [811.
DR. JOHN T. HARRINGTON: In contrast to the early report of
Rubini in 1961 [51j, Healy and colleagues demonstrated no
effect of diuretic-induced potassium depletion on urine concen-
trating ability in 7 hypertensive patients [38]. How do you
reconcile these conflicting reports?
DR. TANNEN: The absence of a significant change in either
concentrating ability or urine acidification in the study by Healy
is difficult to reconcile with the two carefully performed studies
of dietary induced potassium depletion, which have demon-
strated significant effects. It should be noted, however, that the
trends in Healy's study were in a similar direction, although
they failed to achieve statistical significance.
DR. SUSAN FELLNER (Renal Section, Mitchell Hospital): I
agree with your recommendations regarding potassium mainte-
nance. But I think that we as physicians could do a better job in
helping to prevent potassium depletion, particularly with regard
to the issue of dietary salt restriction. A real commitment to the
education of our patients about dietary sodium might prevent at
least some of the diuretic-induced hypokalemia that we see.
DR. TANNEN: I agree. If we could get patients to ingest
approximately 100 mEq/day of sodium, we would tend to
minimize the degree of hypokalemia and would probably in
many instances improve their antihypertensive control as well.
However, even if we do, some patients will, for example,
develop serum potassium levels of 3.5 mEq/liter, which in my
view are not normal. If these people have underlying cardiac
disease, I think a normal serum potassium should be main-
tained, and this probably will require some form of potassium
maintenance therapy.
DR. JORDAN J. COHEN: We all agree that there is a large
group of individuals who have no heart disease and who do not
become very potassium-depleted when given diuretics. If such
individuals are truly at risk from the modest hypokalemia they
manifest, then nature has endowed us with an extremely narrow
margin for error in maintaining potassium homeostasis. There
being no evidence to the contrary, I prefer to believe that the
mammalian organism is more resilient than that. Only if one
believes otherwise would it be justifiable to expose patients
treated with diuretics routinely—and I emphasize routinely—to
the admittedly small but definite risk of hyperkalemia from
potassium maintenance therapy. Do you agree?
DR. TANNEN: I should have mentioned whom I would not
treat. In view of our current knowledge of the risks associated
with hypokalemia and of the costs and risks of potassium
maintenance therapy, at present I don't think the weight of
evidence is sufficient to subject the group of patients who don't
have underlying, detectable cardiac disease to potassium-main-
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tenance therapy. I am not sure what fraction of the hyperten-
sive population that encompasses, but certainly more patients
receiving antihypertensive therapy don't have detectable cardi-
ac disease than do.
DR. COHEN: There are several bothersome issues about the
reported relationship between hypokalemia and malignant ven-
tricular arrhythmias in the setting of an acute myocardial
infarction. First, as you noted, no firm evidence exists for a
cause-and-effect relationship; hypokalemia in this setting might
be merely a marker, especially in view of the known effects of
catecholamines in shifting potassium intracellularly. Second,
because in many of the reported cases hypokalemia was docu-
mented only after successful resuscitation from the arrhyth-
mias, we must consider, as you did, the question of whether
hypokalemia was the consequence of the treatment (for exam-
ple, alkali infusion) or of the stress (such as catecholamines) or
of something else. Finally, as you also noted, a substantial
subset of patients who are admitted with an acute MI and
hypokalemia and who develop ventricular tachycardia or fibril-
lation have never been exposed to diuretics. And in those who
had been receiving diuretics, we don't know how many also had
been treated with potassium supplements or potassium-sparing
agents and developed hypokalemia anyway. But the dilemma
here is the following: If one is convinced that hypokalemia in
the aftermath of a myocardial infarction promotes malignant
arrhythmias, and one wants to do something to prevent this
complication, one would have to give potassium supplements to
everybody in the country who is at potential risk of developing
an MI, whether they were receiving diuretics or not. Of course,
such a strategy is absurd.
DR. TANNEN: Let's again consider the individuals who have
an acute myocardial infarction and have not been preexposed to
diuretics. Presumably their hypokalemia is not the result of
antecedent potassium depletion but instead reflects an intracel-
lular shift of potassium. There really wouldn't be any way to
pretreat people with potassium to prevent that from happening
unless we were going to propose making everybody walk
around substantially hyperkalemic. Alternatively, some have
suggested that the antiarrhythmic effects of therapy with beta
blockers might be mediated through inhibition of epinephrine-
mediated cellular potassium uptake, but there is no firm evi-
dence in this regard 181]. Thus, with the possible exception of
therapy with beta blockers, there is no prophylactic therapy for
the group with normal potassium homeostasis that is potentially
at risk for a myocardial infarction. But we can diminish the
likelihood for hypokalemia in the diuretic-treated patients at
risk for myocardial infarction by providing them with potassium
maintenance therapy.
DR. MARSHALL LINDHEIMER (Renal Section, Mitchell Hos-
pital): Let's change the discussion from the pros and cons of
potassium maintenance therapy to another aspect of the pa-
tient's problems. This patient's serum sodium level of 116 mEq/
liter reminds me of a series of patients described by Dr.
Fichman and coworkers more than a decade ago [119]. In these
patients, severe hyponatremia was associated with diuretic-
induced hypokalemia, and one of the causes considered was the
"inappropriate" secretion of vasopressin. Would you care to
speculate on the cause of the hyponatremia in this patient?
DR. TANNEN: In this particular patient, the low urinary
sodium and chloride suggested that volume depletion at least
partially accounted for the hyponatremia. Although her hypo-
natremia ultimately resolved in response to concurrent treat-
ment with NaCI and KC1, it didn't correct as rapidly as I would
have anticipated with uncomplicated sodium depletion. No
other reason for the development of hyponatremia was detect-
ed. Prior to discharge from the hospital, she was able to sustain
a normal serum sodium concentration in the absence of specific
therapy. Thus she might fit into the group of diuretic-treated
hypokalemic patients who appear to manifest "inappropriate"
ADH secretion. The patients reported by Fichman et al devel-
oped hyponatremia in the absence of detectable volume deple-
tion, and these authors speculated that hypokalemia might have
modified either the osmoreceptors or the releasing mechanism
for vasopressin. Perhaps supporting their hypothesis, recent
data indicate that vasopressin levels are increased in potassium-
depleted rats, and that the elevated levels appear to be a
defense mechanism for protecting systemic hemodynamics
[120]. On the other hand, this phenomenon has been described
mainly in the elderly population, so I always have wondered
whether mechanisms other than hypokalemia might be at play.
For example, might a subset of the elderly population have
baroreceptor mechanisms that can be activated with lesser
degrees of volume contraction than in younger individuals, so
that we don't recognize the degree of volume contraction as
being a stimulus? I think it would be quite interesting to study
this phenomenon more carefully in terms of what we now
understand about the nonosmotic release of vasopressin.
DR. BRIAN DUFFY (Attending Nephrologist, Michael Reese
Hospital): What is your approach to the unusual patient who
becomes severely hypokalemic during administration of small
doses of diuretics?
DR. TANNEN: If a hypertensive patient develops diuretic-
induced hypokalemia to a level less than 3.0 mEq/liter, I believe
it is appropriate to evaluate for primary aldosteronism. Another
consideration would be renal artery stenosis; patients with this
disorder can have significant degrees of secondary hyperaldo-
steronism and develop hypokalemia on that basis, as can those
with other forms of mineralocorticoid or glucocorticoid excess.
Of course, other causes of potassium depletion also should be
kept in mind, including vomiting and laxative abuse. In effect,
the patient with severe hypokalemia needs to be completely
worked up. Of course this is not the case with the average
patient taking diuretics, who is mildly hypokalemic; in this
situation, there is a very clear explanation.
DR. COHEN: If you proceed with that algorithm, you will
work up a lot of people to obtain a very low yield of patients
with primary aldosteronism. By definition, you are talking
about patients who were normokalemic prior to the introduc-
tion of diuretics, because presumably you would have already
pursued the possibility of primary aldosteronism had they been
spontaneously hypokalemic. Thus we are considering maybe as
many as 5% of patients treated with diuretics who will become
hypokalemic to this degree. I believe the number of patients in
that subset who have primary aldosteronism will be extremely
small.
DR. TANNEN: I agree that the yield might be quite low. But
the workup for primary aldosteronism is not difficult. Screening
by the measurement of plasma renin is easy, and the finding of
normal renin levels should eliminate the vast majority of
patients from requiring further evaluation.
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DR. SERAFINO GARELLA (Renal Division, Michael Reese
Hospital): You mentioned that the level of dietary sodium
intake least likely to be associated with major potassium deficits
in patients on diuretic therapy is approximatley 100 mEq/day.
Would you speculate on the mechanisms responsible for the
linkage between a higher level of salt intake and the increased
likelihood of potassium wasting?
DR. TANNEN: In the study by Ram and coworkers, potassium
depletion was significantly greater when diuretics were taken
for 4 weeks with a dietary sodium content of approximately 200
mEq/day as compared with 70 mEq/day [23]. Aldosterone
levels were higher in the group on the lower sodium intake.
Thus, one could speculate that the higher sodium intake result-
ed in greater fluid and sodium delivery to the distal nephron,
and thereby resulted in heightened urinary losses of potassium;
but the actual underlying mechanism was not subjected to
rigorous investigation. It is of interest that Wilcox and col-
leagues recently reported no evidence of negative potassium
balance in normal volunteers ingesting a sodium intake of 270
mEq/day during 3 days of furosemide treatment [121]. Obvious-
ly the two sets of studies were carried out in different fashions,
but the possibility does exist that the kaliuretic response might
differ between normotensive and hypertensive individuals.
DR. KAI LAU (Renal Division, Michael Reese Hospital):
There are at least two reasons why potassium balance studies in
humans might underestimate the true magnitude of the potassi-
um deficits induced by diuretics. (1) Many hypertensive pa-
tients ingesting a low-salt diet are also taking salt substitutes,
which are generally potassium-rich and which we often don't
know about because of the absence of a careful history. (2) We
are beginning to uncover increasing numbers of patients who
take variable amounts of prostaglandin inhibitors without a
prescription. If this piece of history is not specifically sought,
one can miss intervals of variable lengths over which renal
potassium retention can have occurred. Wouldn't these two
factors obscure the true magnitude as well as the incidence of
potassium deficits?
DR. TANNEN: I would agree with you that either of these
phenomena could influence the degree of potassium depletion
and of hypokalemia in patients taking diuretics. I suspect,
however, that these two possibilities have not had a meaningful
impact on the incidence and magnitude of potassium depletion
reported in the literature. First, the data on the incidence and
degree of hypokalemia include an enormous number of pa-
tients, the studies have been reported over several decades, and
the data are all reasonably consistent. Second, in the studies
that determined actual potassium deficits using either ex-
changeable or total body potassium measurements, the degree
of hypokalemia was comparable to that reported in the volumi-
nous data that measured only blood levels. Thus the potassium
deficit appears to have been measured on a representative
sample.
DR. COHEN: Dr. Lau's question brings up another point. You
commented that Lawson's data published in the '70s and
collected retrospectively from several hospitals [1151 might
have overestimated the current risk of hyperkalemia, even in
the hospitalized patient, because we now use potassium supple-
ments and potassium-sparing agents more cautiously and with
more understanding of the hazards. But it's also true that
patients are now being exposed to several new antikaliuretic
drugs that potentially compound the risk of hyperkalemia; I'm
referring to the nonsteroidal antiinflammatory agents, the beta
blockers, captopril, and no doubt others.
DR. TANNEN: That's a good point. Clearly if one is going to
use potassium-sparing drugs or potassium supplementation, all
the drugs that can predispose towards development of signifi-
cant hyperkalemia must be kept in mind. Also, great care
should be exercised in treating insulin-dependent diabetics with
any potassium maintenance regimen. Finally, the elderly and
individuals with decreased GFRs who are also at increased risk
for hyperkalemia need to be individualized so that we can
assess the need for and the risks versus benefits of potassium
therapy.
DR. JAMES BOURDEAU (Renal Division, Michael Reese Hos-
pital): In experimental animals not given diuretics, chronic
administration of potassium chloride results in a phenomenon
of potassium adaptation, whereby acute potassium loads are
excreted by the kidneys more rapidly than normal. Do patients
who are taking diuretics and who are being given supplements
of potassium chloride also develop potassium adaptation? That
is, are they able to excrete an acute potassium load more
rapidly than do normal individuals? If so, and if their potassium
chloride supplementation were stopped, would they be at
increased risk for developing hypokalemia?
DR. TANNEN: I would assume not. I suspect that the induc-
tion of adaptation requires at least transitory hyperkalemia.
However, I am unaware of any studies that have directly tested
the question you raise.
DR. BUSHINSKY: As you noted, a reasonable correlation
exists between the serum potassium concentration and potassi-
um balance over a wide range of potassium depletion. Yet you
also noted that the fall in serum potassium observed with three
different diuretic agents correlated poorly with the change in
potassium balance. Could you comment on this apparent
contradiction?
DR. TANNEN: I don't have a good answer to your question,
but I would caution that the data summarized in Table 3
represent a composite of multiple studies using different mea-
surement techniques, and with some variation in sodium intake.
In the furosemide group, which has the lowest patient number,
elimination of the 12 patients who were ingesting a sodium
intake of 196 mEq/day [23] reduces the mean potassium deficit
to 132 mEq. This would square better with the lower decrement
in plasma potassium, but I think there are insufficient total body
potassium data to make a firm comparison of the furosemide
and thiazide data.
DR. JEROME P. KASSIRER: Dr. Tannen, whether or not one
believes that it is appropriate to prevent hypokalemia in diuret-
ic-treated patients depends in part on one's strength of convic-
tion about the correlation between hypokalemia and life-threat-
ening rhythm disturbances. John Harrington and I have a
somewhat different view from yours about the validity of this
correlation. A recent study by Nordrehaug, which you did not
mention, is a case in point. Nordrehaug concluded, in a study of
patients with acute myocardial infarction complicated by seri-
ous rhythm disturbances, that hypokalemia increased the
chance of a serious arrhythmia [1221. Careful review of his
study, however, discloses that other factors, including digitalis
administration and preexisting coronary artery disease, could
have explained the higher frequency of rhythm disturbances in
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the hypokalemic group. This comment raises questions about
the validity of the experimental design, a problem we have
addressed before [5]. Even if one accepts the Nordrehaug
report as valid, however, we are concerned that the fraction of
patients developing ventricular fibrillation was the same or
higher in patients with hyperkalemia as in two groups of his
patients with hypokalemia. This finding speaks to our concern
that the risks of hyperkalemia need to be balanced against the
risks of hypokalemia. Can you address these issues?
DR. TANNEN: There is one very recent report by Nordrehaug
and coworkers that I did not mention [1231. In this study, 60
patients with an acute myocardial infarction and no treatment
with cardioactive drugs were evaluated prospectively. This
study also delineated a significant negative correlation between
serum potassium level and ventricular tachycardia, supporting
other retrospective analyses suggesting that digitalis does not
explain this relationship [56, 57, 81, 84].
You are correct in pointing out that in the study by Nordre-
haug, as well as in several other studies, the incidence of
ventricular tachycardialfibrillation was increased by hyperkale-
mia as well as by hypokalemia [56, 57, 83, 84]. Dyckner and
coworkers suggest that the hyperkalemia is secondary to hy-
poxia and acidosis and that the increase in ventricular arrhyth-
mias may be related to the more serious condition of these
patients, but the authors do not provide any data on this point
[831. Certainly the cardiac risks of severe hyperkalemia are
undisputable. In my view, the goal should be maintenance of
normal potassium balance in patients at risk for myocardial
infarction in order to reduce the risk of sudden death before
they arrive at the hospital.
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